Through integrated genomic analysis, structural modeling, and drug affinity prediction, we aim to elucidate the potential pathogenic mechanisms of this novel GATA2 variant and its implications for therapeutic targeting in lower-grade gliomas. Here, GATA2 is linked to glioma.